BioMarin Pharmaceutical Stock Forecast

Stock Price Forecast

The 18 analysts with 12-month price forecasts for BioMarin Pharmaceutical stock have an average target of 88.22, with a low estimate of 55 and a high estimate of 119. The average target predicts an increase of 65.52% from the current stock price of 53.30.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$55	$88.22	$94	$119
Change	+3.19%	+65.52%	+76.36%	+123.26%

* Price targets were last updated on Mar 11, 2026.

Analyst Ratings

The average analyst rating for BioMarin Pharmaceutical stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	6	6	7	6	6	6
Buy	9	8	8	7	8	8
Hold	5	6	6	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	20	21	17	18	18

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Geoff Meacham B of A Securities	B of A Securities	Strong Buy Maintains $97 → $85	Strong Buy	Maintains	$97 → $85	+59.47%	Mar 11, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $80 → $105	Buy	Maintains	$80 → $105	+97.00%	Mar 4, 2026
Ilya Zubkov Freedom Broker	Freedom Broker	Strong Buy Maintains $100 → $105	Strong Buy	Maintains	$100 → $105	+97.00%	Mar 2, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates $55	Hold	Reiterates	$55	+3.19%	Mar 2, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $98 → $104	Strong Buy	Maintains	$98 → $104	+95.12%	Feb 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.71B

from 3.22B

15.02%

from 3.22B

Revenue Next Year

4.16B

from 3.71B

12.23%

from 3.71B

EPS This Year

4.37

from 1.80

142.29%

from 1.80

EPS Next Year

5.77

from 4.37

31.95%

from 4.37

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.85B	2.10B	2.42B	2.85B	3.22B	3.71B	4.16B
Revenue Growth	-0.76%	13.53%	15.42%	17.97%	12.87%	15.02%	12.23%
EPS	-0.35	0.75	0.87	2.21	1.80	4.37	5.77
EPS Growth	-	-	16.00%	153.71%	-18.24%	142.29%	31.95%
Forward PE	-	-	-	-	-	12.19	9.24
No. Analysts	-	-	-	-	-	27	24

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	4.2B	4.8B
Avg	3.7B	4.2B
Low	3.3B	3.3B

Revenue Growth

Revenue Growth	2026	2027
High	29.5%	30.8%
Avg	15.0%	12.2%
Low	1.2%	-11.9%

EPS Forecast

EPS	2026	2027
High	6.34	9.18
Avg	4.37	5.77
Low	2.97	3.48

EPS Growth

EPS Growth	2026	2027
High	251.4%	109.9%
Avg	142.3%	31.9%
Low	64.5%	-20.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.